CoChat

Use of incretin-based therapies in women using hormone replacement therapy (HRT)

Mukherjee, Annice, Ghaem-Maghami, Sadaf, Syed, Akheel A · 2025 · Post Reproductive Health

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Abstract

Semaglutide and tirzepatide result in delayed gastric emptying and gastrointestinal side effects are common. The impact of these medications on efficacy of co-prescribed oral hormone medications within HRT are unknown. The effect on absorption and bioavailability of combination oral contraceptive (COC) varies by incretin-based products. Reduced bioavailability is seen with tirzepatide 22 . Semaglutide may confer similar effects through its effects on gastric emptying, but small studies show no adverse effects on COC absorption 23,24 . Eli Lilly has provided data showing that administration of a COC (0.035 mg ethinyl estradiol plus 0.25 mg norgestimate) in the presence of a single dose of tirzepatide (5 mg) resulted in a reduction of oral contraceptive Cmax (maximum drug concentration) by 55 to 66%, with a 16 to 23% reduction in AUC (Area Under the Curve) and a delay in Tmax (time to achieve Cmax) of 2.5 to 4.5 hours. These effects may be due to the impact of tirzepatide on gastric emptying. The company therefore advises patients using a COC to switch to a non-oral contraceptive method, or to add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with tirzepatide 25 .

Overview

Integrity signals

Registry

Crossref · 10.1177/20533691251343069

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 23 references

Research works printed but not linked: 2

  1. Kapkayeva S, Ginzburg R. Possible drug interaction between GLP-1 agonist and oral contraceptives. Reproductive health access project, 2025. https://www.reproductiveaccess.org/resource/possible-drug-interaction-between-glp-1-agonist-and-oral-contraceptives/.
  2. Zentiva UK. Progesterone 100 mg Capsules, soft [summary of product characteristics]. Zentiva. 2024. https://www.medicines.org.uk/emc/product/15401/smpc#gref.

Cited by

See all 3

Metadata

Authors
Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A.
Affiliations
  • Spire Manchester Hospital (GB)
  • Department of Gynaecological Oncology, Imperial College London, London, UK
  • University of Manchester (GB)
Corresponding author
Mukherjee, Annice
Venue
Post Reproductive Health
Published
2025-05-16
Volume
31
Issue
2
Pages
127-131
ISSN
  • 2053-3370 (ISSN-L)
  • 2053-3691
  • 2053-3705
OpenAlex
W4410426997
Cited by
3
References
24
Citations by year
2026: 2 · 2025: 1
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Post Reproductive Health (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
Astellas, Novartis, Lilly
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
incretin-based therapy, hormone replacement therapy, women, type 2 diabetes, postmenopausal women, drug interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of incretin-based therapies in women using hormone replacement therapy (HRT). https://app.cochat.ai/papers/10.1177/20533691251343069
The paper
Mukherjee, A., Ghaem-Maghami, S., & Syed, A. A. (2025). Use of incretin-based therapies in women using hormone replacement therapy (HRT). Post Reproductive Health. https://doi.org/10.1177/20533691251343069

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.